Furthermore, Sanger sequencing with microdissection confirmed that each component—small cell type NEC from EUS-FNA, as well as large cell type NEC and CIS from the resected specimen—shared the same KRAS mutation (p.G12V) (Fig. 7). Here, KRAS is linked to in situ carcinoma.